Immutep (ASX:IMM) ended the fiscal third quarter with a cash balance of AU$92.5 million, according to a Tuesday filing with the Australian bourse.
It also has short-term bank deposits of AU$53.8 million, the filing said.
The clinical-stage biotechnology company saw progress in its ongoing trials during the quarter. This year, it expects analysis and safety assessment reports for treatments of breast cancer and autoimmune disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.